AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32189664
Drug: 40 HBOTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 HBOTs at 150 kPa/60 minutes, once daily, 5 days per week for 8 weeks
Trial: 32109425
Drug: Gefapixant 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefapixant 7.5 mg
Trial: 32109425
Drug: Gefapixant 20
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 20 mg
Trial: 32109425
Drug: Gefapixant 50
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 50 mg
Trial: 35679950
Drug: Vonoprazan triple
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan triple therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Trial: 35679950
Drug: Vonoprazan dual
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Trial: 35679950
Drug: Lansoprazole triple
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole triple therapy (30 mg lansoprazole; 1 g amoxicillin; 500 mg clarithromycin)
Trial: 35679950
Drug: Vonoprazan triple
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan triple therapy
Trial: 35679950
Drug: Vonoprazan dual
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan dual therapy
Trial: 35679950
Drug: Lansoprazole triple
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole triple therapy
Trial: 35750038
Drug: Atezolizumab 840
RxNorm normalized name: atezolizumab 840 MG in 14 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy
Trial: 35750038
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with nab-paclitaxel and anthracycline-based chemotherapy
Trial: 35750038
Drug: Atezolizumab 840
RxNorm normalized name: atezolizumab 840 MG in 14 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Trial: 35750038
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Trial: 35750038
Drug: Atezolizumab 840
RxNorm normalized name: atezolizumab 840 MG in 14 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 840 mg every 2 weeks
Trial: 32977404
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2000 mg DHA + 400 mg EPA/day)
Trial: 32977404
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of curcumin and fish oil
Trial: 33473019
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug (NSAID)
Trial: 33473019
Drug: NSAID and
RxNorm normalized name: methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAID and antihistaminic drug combination
Trial: 93178847
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa therapy for 26 weeks
Trial: 36494045
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi intervention, remotely delivered, twice a week for 12 weeks
Trial: 36494045
Drug: Wellness control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellness control condition, remotely delivered, twice a week for 12 weeks
Trial: 32139212
Drug: RHB-102 (24-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHB-102 (24-mg bimodal-release ondansetron)
Trial: 32215727
Drug: Drug plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug plus psychotherapy (DPP) with olanzapine and metacognitive training (MCT) for 8 weeks
Trial: 32215727
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (DT) with olanzapine for 8 weeks
Trial: 32215727
Drug: Drug plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug plus psychotherapy (DPP) with olanzapine and MCT
Trial: 32215727
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (DT) with olanzapine
Trial: 34034273
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L PEG + 290 µg linaclotide (2 L PEG + L group)
Trial: 34034273
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L PEG
Trial: 33644749
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training
Trial: 33980234
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) with metronidazole (MET) and oral hygiene instructions (OHI)
Trial: 33980234
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions (OHI) only
Trial: 32195649
Drug: Iclaprim 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim 80 mg
Trial: 32195649
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg administered intravenously every 12 hours for 5-14 days
Trial: 35212648
Drug: Inhaled lavender
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled lavender essence (diluted with sweet almond oil at a ratio of 1:10) administered before cannulation during 12 HD sessions.
Trial: 33610374
Drug: IIV4-HD 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-HD 60 µg
Trial: 33610374
Drug: IIV4-SD (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-SD (15 µg HA/strain)
Trial: 35343725
Drug: Relaxation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation group therapy (RGT)
Trial: 32991788
Drug: Aripiprazole (ARI)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (ARI) 10 mg
Trial: 32991788
Drug: Olanzapine (OLA)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLA) 5 mg
Trial: 32205684
Drug: Epidural Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural Fentanyl and Bupivacaine (10-mL solution of 50 mcg of Fentanyl, 0.125% Bupivacaine, and 0.9% saline solution)
Trial: 32628554
Drug: Low-Dose Rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Rivaroxaban plus Aspirin
Trial: 32960053
Drug: BAY 1214784,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1214784, an orally available spiroindoline derivative, administered once daily
Trial: 32996592
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with telapristone acetate (12 mg/day)
Trial: 32609979
Drug: Amoxicillin for
RxNorm normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin for 5 days
Trial: 33735146
Drug: MUSTCOOL cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MUSTCOOL cooling patch
Trial: 36289399
Drug: Bamlanivimab 7,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 7,000 mg
Trial: 35002538
Drug: Wrist-ankle acupuncture-moxibustion
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist-ankle acupuncture-moxibustion and hot compression with Chinese herbal medicine
Trial: 32532310
Drug: Ropivacaine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 75 mg
Trial: 35999521
Drug: Flash dose
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flash dose of preoperative corticosteroids
Trial: 32641470
Drug: Naproxen (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (both doses)
Trial: 35713449
Drug: Nalbuphine in
RxNorm normalized name: nalbuphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine in patient-controlled intravenous analgesia
Trial: 32427667
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support for overcoming treatment-related challenges
Trial: 32887707
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump therapy (SAP) for 1 year
Trial: 32887707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (multiple daily injection therapy)
Trial: 36241128
Drug: eRAPID (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eRAPID (weekly online symptom reporting for 12, 18 & 24 weeks)
Trial: 34319247
Drug: SMS text
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text messaging intervention (daily for the first 4 weeks, 5 messages on week 5, 3 messages each in weeks 6 and 7, and 1 message weekly from week 8 to week 52)
Trial: 34319247
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly SMS text message reminding of next study appointment and importance of the study)
Trial: 33664081
Drug: 3.375‐4.5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.375‐4.5 g intravenous piperacillin‐tazobactam
Trial: 33664081
Drug: 1‐2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐2 g intravenous cefoxitin
Trial: 32815891
Drug: Telephone-based administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based administration of the ABILHAND
Trial: 32815891
Drug: Face-to-face administration
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face administration of the ABILHAND
Trial: 34168029
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) - single dose of 40 mg/kg
Trial: 32698957
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement (109 CFU/day) for 8 weeks
Trial: 34842215
Drug: Integral Meditation
RxNorm normalized name: Meditize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral Meditation (IM) program consisting of 12 weekly meditation classes after the afternoon shift
Trial: 32605509
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening with low-dose computed tomography
Trial: 32683992
Drug: Home exercises
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home exercises (10 min daily for 3 weeks)
Trial: 32155018
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination therapy with 5% imiquimod cream, 2% 5-FU solution, and 0.1% tretinoin cream, applied five nights per week under occlusion for a treatment goal of 30 total applications.
Trial: 32576275
Drug: Residential behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential behavior therapeutic smoking cessation therapy
Trial: 32576275
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient behavior therapeutic smoking cessation group therapy
Trial: 35154550
Drug: Hydromorphone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone group (spinal anesthesia with 0.5% ropivacaine and 75 μg hydromorphone)
Trial: 35154550
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (spinal anesthesia with 0.5% ropivacaine and 150 μg morphine)
Trial: 33209056
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group
Trial: 33582693
Drug: Standard Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Triple Drug Therapy
Trial: 33582693
Drug: Sequential Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Drug Therapy
Trial: 35108620
Drug: Brief hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief hypnotic induction with reduced preoperative local anesthetics (Dave Elman technique)
Trial: 35108620
Drug: Regular preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular preoperative local anesthetics without brief hypnotic induction (standard care)
Trial: 35108620
Drug: Brief hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief hypnotic induction
Trial: 34644368
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low carbohydrate diet (VLCBD) (<20g daily intake)
Trial: 39475399
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (control group)
Trial: 36038516
Drug: Multifunctional laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifunctional laser photoelectric platform combined with hydroxychloroquine (0.2 g, twice a day)
Trial: 36038516
Drug: Hydroxychloroquine sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate tablets (0.2 g, twice a day)
Trial: 35429850
Drug: Bilateral GNB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral GNB with 0.125% bupivacaine, 0.5 xylocaine, and 4 mg dexamethasone
Trial: 34256820
Drug: Increased maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased maternal speech exposure (treatment group, n = 21)
Trial: 32543161
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (2 ml, 0.25 mg/ml suspension for nebulizer) administered within 6 hours of birth and a second dose 12 hours later.
Trial: 32543161
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation (2 ml of distilled sterile water).
Trial: 35232482
Drug: Chiropractic care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic care (CC)
Trial: 34818400
Drug: CAF +
RxNorm normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAF + L-PRF
Trial: 32943239
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted an extra daily cup of tea consumption
Trial: 34921756
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg/day for 35 days
Trial: 33499679
Drug: Sugammadex calculated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex calculated using corrected body weight (CBW), 4 mg/kg
Trial: 33499679
Drug: Sugammadex calculated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex calculated using total body weight (TBW), 4 mg/kg
Trial: 34193056
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/daily
Trial: 32108022
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and statins (oral drugs)
Trial: 36013137
Drug: Gentle Touch
RxNorm normalized name: Gentle Touch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentle Touch Therapy (GTT)
Trial: 35259147
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (synchronized radiofrequency and HIFEM)
Trial: 33687872
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral anticoagulation (OAC) with direct oral anticoagulants (DOACs)
Trial: 33599431
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1000 mg daily for 8 weeks)
Trial: 33599431
Drug: Medium chain
RxNorm normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium chain triglyceride (1000 mg daily for 8 weeks)
Trial: 35489044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (customary treatment)
Trial: 34503367
Drug: IM20-4 (20μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM20-4 (20μg, 4 doses)
Trial: 34503367
Drug: IM60-4 (60μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM60-4 (60μg, 4 doses)
Trial: 34503367
Drug: Short-term high-strength
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term high-strength vaccination group (4 doses)
Trial: 34503367
Drug: Standard vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccination group (3 doses)
Trial: 33451954
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg/kg as a bolus before aortic cross‐clamping and 2 mg/kg mixed in the cardioplegia solution)
Trial: 32138631
Drug: EG-1962 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG-1962 (600 mg intraventricular dose)
Trial: 32138631
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral nimodipine)
Trial: 36749631
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonism
Trial: 34391812
Drug: 0.9% spinosad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% spinosad topical suspension
Trial: 33179988
Drug: QSPR modelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QSPR modelling of aliphatic compounds
Trial: 33179988
Drug: QSPR modelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QSPR modelling of phenyl‐based compounds
Trial: 35422053
Drug: Oral-transmucosal haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-transmucosal haloperidol 2.5 mg
Trial: 35422053
Drug: Oral-transmucosal olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-transmucosal olanzapine 5 mg
Trial: 32293657
Drug: Conventional wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional wound treatment (CWT)
Trial: 36056388
Drug: Personalised intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personalised intervention programme including modules such as Brief messaging, Clinical medication review, Medication schedule, Reminding messaging, Medication dispensing systems, Smart messaging, Referral to general practitioner, Unguided web-based Self Help Application for low mood.
Trial: 33707410
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (weekly sessions from January 22 to March 11, 2020)
Trial: 35964417
Drug: Amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (10 or 20 mg)
Trial: 35964417
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 or 400 mg)
Trial: 32496448
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy (gDT)
Trial: 34836275
Drug: Vinegar group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinegar group (1.5 g acetic acid/day as liquid vinegar)
Trial: 34836275
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.015 g acetic acid/day as a pill)
Trial: 35385090
Drug: PARS intervention
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PARS intervention (1-session secondary prevention module administered by trained SUD counselors)
Trial: 33564993
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine and morphine (ITBM) group, n = 45
Trial: 32233962
Drug: Obstetrician-gynecologists retrieving
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetrician-gynecologists retrieving medication safety information during clinical visits